Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Ciforadenant - Corvus Pharmaceuticals

Next Previous
Drug Profile

Ciforadenant - Corvus Pharmaceuticals

Alternative Names: CPI-444; V 81444

Latest Information Update: 05 Jan 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Vernalis
  • Developer Corvus Pharmaceuticals; Genentech; M. D. Anderson Cancer Center; Vernalis
  • Class Amines; Antineoplastics; Antiparkinsonians; Behavioural disorder therapies; Furans; Pyridines; Pyrimidines; Small molecules; Triazoles
  • Mechanism of Action Adenosine A2A receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Renal cell carcinoma
  • Phase I/II Non-small cell lung cancer
  • Phase I Multiple myeloma; Solid tumours
  • No development reported Attention-deficit hyperactivity disorder; Cancer; Parkinson's disease

Most Recent Events

  • 05 Jan 2024 Ciforadenant is still in phase I trials for Solid tumours in Australia and the USA (NCT03454451)
  • 04 Jul 2023 Phase-II clinical trials in Renal cell carcinoma (First-line therapy) (PO) before July 2023 (Corvus Pharmceuticals pipeline, July 2023)
  • 19 Feb 2023 Corvus Pharmaceuticals comletes a phase I/Ib trial for Cancer (Second-line therapy or greater, Late-stage disease, Combination therapy) in USA and Australia (PO) (NCT03454451)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top